寡转移性前列腺癌的放射治疗:系统综述
证据以回顾性病例系列为主,缺乏统一的寡转移定义;SBRT等MDT显示高局部控制率,部分患者在2年后无疾病进展,激素敏感与去势抵抗患者均如此。放疗剂量和照射野差异较大,68Ga-PSMA PET/CT分期应用急剧增加,前瞻性研究正在进行。
要点
- 证据以回顾性病例系列为主,寡转移尚无统一定义。
- 放疗MDT局部控制率高,部分患者2年后无进展。
- 激素敏感与去势抵抗患者均可见上述获益。
核心结论
- 本综述纳入寡转移性前列腺癌原始文献数量最多,显示MDT的治疗潜力与挑战。
- 前瞻性研究正在进行,将提供进一步高级别证据。
主要发现
- 证据主要由回顾性病例系列组成,寡转移尚无一致精确的定义。
- 多数研究者似乎认同需区分「同时性」与「异时性」寡转移性疾病。
- 放疗作为MDT显示高局部控制率,小但相关比例的患者2年后无疾病进展。
- 该结果在激素敏感与去势抵抗性前列腺癌中均成立。
- 68Ga-PSMA PET/CT用于分期急剧增加,各研究放疗剂量和照射野差异很大。
临床怎么用
- 放疗MDT可用于寡转移性前列腺癌,包括骨转移的SBRT及孤立淋巴结寡转移的SBRT联合预防性择区放疗。
- 应区分同时性与异时性寡转移,并关注激素敏感状态及复发模式。
局限性
- 证据 largely 为回顾性病例系列,缺乏统一寡转移定义。
- 各研究放疗剂量和照射野差异显著,预后/预测因素仍在探索中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Due to improved imaging sensitivity, the term "oligometastatic" prostate cancer disease is diagnosed more often, leading to an increasing interest in metastasis-directed therapy (MDT). There are two types of radiation based MDT applied when treating oligometastatic disease: (1) stereotactic body radiation therapy (SBRT) generally used for bone metastases; or (2) SBRT for isolated nodal oligometastases combined with prophylactic elective nodal radiotherapy. This review aims to summarize current evidence data, which may shed light on the optimal management of this heterogeneous group of patients. METHODS: A systematic review of the Medline database through PubMed was performed according to PRISMA guidelines. All relevant studies published up to November 2020 were identified and screened. Fifty-six titles were included. Besides outcome parameters, different prognostic and predictive factors were assessed, including site of metastases, time between primary treatment and MDT, use of systemic therapies, hormone sensitivity, as well as pattern of recurrence. FINDINGS: Evidence consists largely of retrospective case series and no consistent precise definition of oligometastasis exists, however, most investigators seem to acknowledge the need to distinguish between patients presenting with what is frequently called "synchronous" versus "metachronous" oligometastatic disease. Available data on radiotherapy as MDT demonstrate high local control rates and a small but relevant proportion of patients without progressive disease after 2 years. This holds true for both hormone sensitive and castration resistant prostate cancer diseases. The use of 68Ga-PSMA PET/CT for staging increased dramatically. Radiation doses and field sizes varied considerably among the studies. The search for relevant prognostic and predictive factors is ongoing. CONCLUSIONS: To our best knowledge this review on oligometastatic prostate cancer included the largest number of original articles. It demonstrates the therapeutic potential and challenges of MDT for oligometastatic prostate cancer. Prospective studies are under way and will provide further high-level evidence.
引用
- Rogowski P, Roach M, Schmidt-Hegemann NS, et al. Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol. 2021. PMID: 33750437. doi:10.1186/s13014-021-01776-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。